Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2009

01-02-2009 | Concise Article

Antibody response of HIV-infected patients to latent, cerebral and recently acquired toxoplasmosis

Authors: L. Machala, M. Malý, Š. Hrdá, H. Rozsypal, M. Staňková, P. Kodym

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2009

Login to get access

Abstract

The aim of this longitudinal study with 626 HIV-infected patients was to evaluate the capability of serological tests in diagnosing the presence of Toxoplasma gondii infection in HIV-infected patients, as well as the potential impact of various treatment regimes on serological results. Low IgG antibody levels and stable or declining titres predominated. IgM positivity occurred in ten patients (one seroconversion, seven latent, two cerebral toxoplasmosis). Complement fixation test (CFT) titres ≥1:32 imply that the relative risk of cerebral toxoplasmosis is 6.84 (95% confidence interval [CI] 1.44–32.5) but with a predictive value of only 14.0% (95% CI 5.3–27.9). Values of specific antibodies are not biassed by antiretroviral treatment and/or prophylaxis for toxoplasmosis, and the detection of specific antibodies is very useful in the identification of T. gondii infection in the HIV-infected population, but the role of serology in predicting the clinical manifestation of T. gondii infection is limited.
Literature
1.
go back to reference Luft BJ, Remington JS (1992) Toxoplasmic encephalitis in AIDS. Clin Infect Dis 15:211–222PubMed Luft BJ, Remington JS (1992) Toxoplasmic encephalitis in AIDS. Clin Infect Dis 15:211–222PubMed
2.
go back to reference Belanger F, Derouin F, Grangeot-Keros L et al (1999) Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988–1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis 28:575–581 doi:10.1086/515147 PubMedCrossRef Belanger F, Derouin F, Grangeot-Keros L et al (1999) Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988–1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis 28:575–581 doi:10.​1086/​515147 PubMedCrossRef
3.
go back to reference Derouin F, Leport C, Pueyo S et al (1996) Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. AIDS 10:1521–1527PubMed Derouin F, Leport C, Pueyo S et al (1996) Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. AIDS 10:1521–1527PubMed
5.
go back to reference Israelski DM, Chmiel JS, Poggensee L et al (1993) Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr 6:414–418PubMed Israelski DM, Chmiel JS, Poggensee L et al (1993) Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr 6:414–418PubMed
7.
go back to reference Bartlett JG, Gallant JE (2005) 2005–2006 Medical management of HIV infection. Johns Hopkins University Press, Baltimore Bartlett JG, Gallant JE (2005) 2005–2006 Medical management of HIV infection. Johns Hopkins University Press, Baltimore
9.
go back to reference Kodym P, Malý M, Švandová E et al (2001) Toxoplasma in the Czech Republic 1923–1999: first case to widespread outbreak. Int J Parasitol 31:125–132 Kodym P, Malý M, Švandová E et al (2001) Toxoplasma in the Czech Republic 1923–1999: first case to widespread outbreak. Int J Parasitol 31:125–132
12.
go back to reference Reiter-Owona I, Bialek R, Rockstroh J et al (1998) The probability of acquiring primary Toxoplasma infection in HIV-infected patients: results of an 8-year retrospective study. Infection 26:20–25 doi:10.1007/BF02768747 PubMedCrossRef Reiter-Owona I, Bialek R, Rockstroh J et al (1998) The probability of acquiring primary Toxoplasma infection in HIV-infected patients: results of an 8-year retrospective study. Infection 26:20–25 doi:10.​1007/​BF02768747 PubMedCrossRef
13.
go back to reference Zufferey J, Sugar A, Rudaz P et al (1993) Prevalence of latent toxoplasmosis and serological diagnosis of active infection in HIV-positive patients. Eur J Clin Microbiol Infect Dis 12:591–595 doi:10.1007/BF01973636 PubMedCrossRef Zufferey J, Sugar A, Rudaz P et al (1993) Prevalence of latent toxoplasmosis and serological diagnosis of active infection in HIV-positive patients. Eur J Clin Microbiol Infect Dis 12:591–595 doi:10.​1007/​BF01973636 PubMedCrossRef
14.
go back to reference Arendt G, von Giesen H, Hefter H et al (1999) Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand 100:178–184PubMedCrossRef Arendt G, von Giesen H, Hefter H et al (1999) Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand 100:178–184PubMedCrossRef
Metadata
Title
Antibody response of HIV-infected patients to latent, cerebral and recently acquired toxoplasmosis
Authors
L. Machala
M. Malý
Š. Hrdá
H. Rozsypal
M. Staňková
P. Kodym
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2009
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0600-9

Other articles of this Issue 2/2009

European Journal of Clinical Microbiology & Infectious Diseases 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.